Twenty-one patients with advanced non-small cell lung cancer and low performance status (Karnofsky: 40–60) were treated with moderate doses of chemo-radiotherapy. Seven patients (33 %) had partial response and a median survival time of 10 months; 5 patients (24 %) had stable disease and a median survival time of 5 months; 9 patients (43 %) had progression of disease and a median survival time of 6 months. Median survival time for the whole group was 7 months. Toxicity related to treatment was minimal and posttreatment performance status was: stable in 10 patients and improved in 5 responsive patients. We conclude that this therapeutic strategy has some efficacy in this category of patients although it failed to show substantial benefit in terms of survival.
Get full access to this article
View all access options for this article.
References
1.
BerettaG., ClericiM., LabiancaR., MontinariF.: Il carcinoma polmonare non-oat cell.VIII corso AIOM, pp. 761–773, Perugia, 1981.
2.
BitranJ.D., DesserR.K., DeMeesterN.: Metastatic non-oat cell bronchogenic carcinoma: Therapy with cyclophosphamide, doxorubicin, methotrexate and procarbazine (CAMP).JAMA, 240: 2743–2746, 1978.
3.
CarrD.T., MountainC.F.: The staging of lung cancer.Semin. Oncol., 1: 229–234, 1974.
4.
ChahinianA.P., MandelE.M., HollandJ.F.: MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancer.Cancer, 43: 1590–1597, 1979.
5.
DavisS., RambottiP., ParkY.K.: Combination cyclophosphamide, doxorubicin and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung.Cancer Treat. Rep., 65: 955–958, 1981.
EaganR.T., FlemingT.R., SchoonoverV.: Evaluation of response criteria in advanced lung cancer.Cancer, 44: 1125–1128, 1979.
8.
EvansW.K., FeldR., De BoerG.: Cyclophosphamide, doxorubicin and cisplatin in the treatment of non-small cell bronchogenic carcinoma.Cancer Treat. Rep., 65: 947–954, 1981.
9.
GrallaR.J., CvitkovicE., GolbeyR.B.: Cisdichlorodiammineplatinum II (DDP), adriamycin and cyclophosphamide combination chemotherapy in andvanced non-small cell bronchogenic carcinoma.Proc. AACR/ASCO, 19, pp. 353, 1978.
10.
KarnofskyD.A., BurchenalJ.H.: The clinical evaluation of chemotherapeutic agents. In: Evaluation of chemotherapeutic agents.McLeod (Ed.), pp. 191–205, Columbia Univ. Press, New York, 1949.
11.
KnostJ.A., GrecoF.A., HandeK.R., RichardsonR.L., FerM.F., OldhamR.K.: Cyclophosphamide, doxorubicin and cisplatin in the treatment of advanced non-small cell lung cancer.Cancer Treat. Rep., 65: 941–945, 1981.
12.
KreybergL.: Histological typing of lung tumors.International Histological Classification of Tumors.WHO, Geneva, 1977.
13.
LagakosS.W.: Prognostic factors for survival time in inoperable lung cancer. In: Lung Cancer: Clinical Diagnosis and Treatment, StrausM.J. (Ed.), pp. 271–280, Grune & Stratton, New York, 1977.
14.
RuckdeschelJ.C., MehtaC.R., SalazarO.M., CreechR.H., SponzoR.W.: Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, HAM versus CAMP.Cancer Treat. Rep., 65: 959–963, 1981.
SchultzH.P., OvergaardM., SellA.: Inoperable lung cancer treated by X-ray therapy and combination chemotherapy with CCNU, adriamycin and vinblastine (CAVe).Int. J. Radiat. Oncol. Biol. Phys., 6: 1071–1074, 1980.
17.
VoglS.E., MehtaC.R., CohenM.H.: MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung: Low response rate in cooperative group study.Cancer, 44: 864–868, 1979.
